new-onset SLE, 60 patients with longstanding SLE, and 50 healthy subjects in a 3-center prospective study.
Results. Analysis of cardiac enzymes, the presence and size of regional myocardial fibrosis as indicated by late gadolinium enhancement, strain changes, and biventricular ejection fraction did not indicate cardiac impairment in the patients with new-onset SLE. Native myocardial T1 and extracellular volume (ECV), which are extracellular matrix indices, were elevated in the patients with new-onset SLE (mean AE SD 1,369 AE 79 msec versus 1,092 AE 57 msec in the control group for native T1; 32 AE 5% versus 24 AE 3% in the control group for ECV; P < 0.001 for both). The elevation was independent of SLE disease activity.
Conclusion. This is the first study to indicate that drug-naive patients with new-onset SLE, even those with inactive disease, are likely to have silent cardiac impairment. Structural and functional changes in the myocardium are related to SLE disease stage; this finding indicates the value of early detection of myocardial involvement. Native myocardial T1 values and ECV, rather than currently used clinical rheumatic and cardiac indices, could serve as early detection markers of myocardial injury before the presence of visual fibrosis and functional decompensation.
Cardiac involvement, the leading cause of death in patients with systemic lupus erythematosus (SLE) (1), has received increasing attention over the past decade (2) (3) (4) (5) (6) . Several investigators have suggested that the incidence of cardiac impairment ranges from 31% to 70% (1, 4, 7) . Myocarditis or cardiac tamponade might present as an initial manifestation, but cardiac impairment can also remain unrecognized until after autopsy (8, 9) . Cardiac decompensation is another manifestation; however, in most cases, this late-stage phenomenon is usually the first manifestation. To date, methods for detecting SLE-induced cardiac involvement are not ideal, due to the lack of a reliable examination technique. Negative findings on electrocardiography or echocardiography cannot exclude the presence of severe cardiac disease in patients with SLE (2, 6) . Ideal diagnostic tools for elucidating myocardial injury and follow-up are needed. Mavrogeni et al (10) recently developed an algorithm for the evaluation of cardiovascular disease in SLE, which includes clinical and laboratory assessments, electrocardiography, echocardiography, and cardiac magnetic resonance imaging (MRI). From a treatment perspective, however, some researchers have suggested that treating SLE, even when the condition has been stabilized after optimal therapy, does not equally reduce the incidence of cardiovascular disease (11) . Such inconsistent observations highlight the need for exploration of myocardial substrate changes and acute myocardial insults in a timely manner.
Cardiac MRI has enabled the visual assessment of acute inflammation (2) and regional fibrosis by late gadolinium enhancement (LGE) (4, 6) . Previous studies of SLE have shown that cardiac MRI is the best method for the diagnosis of myocardial fibrosis and myocarditis in SLE (2, 4) . For comprehensive assessment of myocardial characteristics, T1 maps and extracellular volume (ECV) have emerged as newly developed imaging techniques and proven ways to track the extracellular changes that lead to an increase in extracellular matrix volume with high accuracy and reproducibility (3, 12) . Unlike the regional viability index (LGE), a number of recent studies have emphasized applications of T1 mapping in cardiac MRI and its potential for "homogenously" detecting diffuse cardiac impairment, advancing our understanding of the role of the extracellular matrix in numerous pathophysiologic processes of the heart (13) (14) (15) . The extracellular matrix volume can be elevated in cases of edema, fibrosis, or necrosis (16) . Puntmann et al (3) demonstrated that T1 mapping might have the potential to detect subclinical myocardial involvement in patients with SLE. T1 maps and ECV are currently recommended by the European Association of Cardiovascular Imaging (17) .
We hypothesized that combining the emerging cardiac MRI sequences will enable the identification of warning signs of cardiac impairment in a timely manner to guide treatment decisions, even in the absence of cardiac symptoms. To our knowledge, this is the first study to assess the cardiac status of drug-naive patients with new-onset SLE without chest discomfort using cardiac MRI techniques. Markers that actually develop early in the disease process, rather than in the late stages, were explored. To determine whether cardiac involvement is related to the course of SLE, patients with longstanding SLE were included as positive controls.
PATIENTS AND METHODS
Patient enrollment. This was a prospective study conducted at 3 centers. Subjects were enrolled at Renji Hospital of Shanghai Jiao Tong University, the Ninth People's Hospital, and Huashan Hospital Baoshan Branch of Fudan University between August 2015 and November 2017. The subjects were divided into the following 3 cohorts: drug-naive patients newly diagnosed as having SLE, patients with longstanding SLE, and age-and sexmatched healthy controls. The protocol was approved by the local institutional review boards, and written informed consent was obtained from each participant.
Patients were diagnosed as having SLE according to the 2012 Systemic Lupus International Collaborating Clinics classification criteria (18) . Drug-naive patients were consecutively enrolled. These patients were diagnosed as having SLE within 1 month prior to study entry, had no cardiac symptoms, and had not received pharmaceutical therapy for SLE. Patients were enrolled regardless of SLE disease activity.
Patients with longstanding SLE were included as positive controls. They were age matched with drug-naive patients, had a disease duration and/or treatment duration of longer than 6 months, and were enrolled regardless of SLE activity. Since subjects with longstanding SLE were recruited more rapidly than those newly diagnosed as having SLE, a ratio of 1.2 patients with longstanding SLE to 1 patient with new-onset SLE was obtained. Recruitment stopped when the number of patients in the group with longstanding SLE reached 60.
The controls were healthy volunteers. Age-matched subjects were potential candidates if they had no medical history of or symptoms of systemic disease or other comorbidities. Healthy candidates were included as negative controls after they demonstrated normal electrocardiographic and echocardiographic results and normal cardiac MRI findings. Control groups were used to establish baseline myocardial T1 and strain values.
The exclusion criteria for all of the groups were as follows: age <18 years or >80 years and any indication of coronary artery disease (CAD), including documented CAD, previous coronary artery computed tomography or angiography confirming >50% stenosis, positive findings on exercise plate test, positive findings on stress echocardiography, or Framingham Coronary Heart Disease Risk Score >5%. Patients with New York Heart Association (NYHA) functional capacity class IV, patients with acute nephritis and severe infection, and patients with standard metallic contraindications to cardiac MRI or an estimated glomerular filtration rate of <30 ml/minute/1.73 m 2 were also excluded from the study.
Clinical cardiac and immunologic assessment. Chest symptoms and a history of myocarditis, pericarditis, or valvular disease were recorded for each patient. Measurements of myocardial enzymes and serologic markers of rheumatic disease were also recorded. Clinical cardiac involvement was evaluated using the NYHA classification and serum markers of cardiac injury (1) . SLE disease activity was assessed using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) (19) (20) (21) by an investigator (Q-RY) who was blinded with regard to the cardiac MRI findings. SLEDAI scores of 0-3 indicated mild disease activity, scores of 4-9 indicated moderate disease activity, and scores of ≥10 indicated severe disease activity. The presence of autoantibodies and antiphospholipid antibodies at the time of recruitment was recorded.
Electrocardiography and echocardiography. The subjects underwent standard electrocardiography and echocardiography (E9; GE Healthcare) within 24 hours of the cardiac MRI scan. Pulmonary artery pressure and ventricular dimensions were recorded. All of the subjects were clinically examined by a consultant immunologist (QG) and cardiologist (J-YS) within 2 days of undergoing the cardiac MRI scan.
Cardiac MRI protocol. Image analysis. All cardiac MRI procedures were performed using a Philips Ingenia 3.0T MRI system. All of the images were sent to the core laboratory for post-processing. Cardiac MRI data analyses were performed by 2 investigators (ZW and XS) who had experience with cardiac MRI and who were blinded with regard to the clinical data.
Biventricular morphology, function, and strain analysis. Volumetric cavity assessment was performed by whole-heart coverage of short-axis slices (7 mm thick with a 3-mm gap). Video images of 3 long-axis views (4-chamber, 2-chamber, and 3-chamber views) were obtained. For detailed sequences, parameters, and measurements, see Supplementary Methods, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40671/ abstract.
Feature tracking, which is a post-processing strain analysis based on video images adding myocardial tissue deformation and displacement information to systolic function, was conducted using voxel tracking post-processing software (22) (Tissue Tracking CMR 42 ; Circle Cardiovascular Imaging). Three-dimensional global peak left ventricular (LV) strain and 2-dimensional peak right ventricular (RV) strain were assessed.
Evaluation of inflammation by T2-STIR. An electrocardiogram-triggered, STIR T2-weighted multislice spin-echo sequence was performed to determine edema and the T2 ratio, which was measured from the region of interest covering the myocardium of the LV, as well as within the skeletal muscle in the same slice. T2 >2 was considered abnormal (23) .
Evaluation of fibrosis by late gadolinium enhancement.
LGE imaging was performed to assess fibrosis with gapless whole-heart coverage of short-axis slices 10 minutes after administration of a cumulative dose of 0.15 mmoles/kg body weight gadobutrol (Gadovist; Bayer HealthCare). Segmented LGE images with at least 3 matching slices with native T1 images were also acquired. The LGE covering the LV volume was analyzed for the presence of regional fibrosis. LGE was expressed as a percentage of the total LV volume, using a 17-segment LV division. The extent of hyperenhanced tissue within each segment was agreed upon by both observers.
T1 mapping and ECV quantification. Native and postcontrast myocardial T1 mapping was performed to determine the ECV in reflecting myocardial edema or fibrosis replacement. See Supplementary Methods for detailed sequences and parameters. The mapping was performed on 3 equatorial end-diastolic LV short-axis slices (basal, mid-ventricle, and apex) before and 15 minutes after administration of an intravenous bolus of 0.15 mmoles/kg gadobutrol.
CVI 42 software (version 5.5.6.1; Circle Cardiovascular Imaging) was used to create parametric maps of MRI relaxation times. The maps were calculated pixel by pixel according to the selection of the user, and native and postcontrast T1 values were measured in the myocardium and blood pool. All 3 slices were measured from base to apex and both pre-and postcontrast; the region of interest was placed on the 16 segments of the myocardium without avoiding the LGE scar. Care was taken to avoid contamination with a signal from the blood pool.
The reported T1 values were obtained by an operator (ZW) who was blinded with regard to the LGE images. In addition to the T1 values of the myocardium and blood pool, on the same day, we measured the hematocrit values in all of the subjects and calculated the ECV according to the formula:
where k = [MR1 myocardium]/[MR1 blood pool] before and after gadolinium contrast injection (where R1 = 1/ T1). (17) . See Supplementary Methods for quality assessment of the T1 maps.
Reproducibility. Twenty-five percent of the patients (including patients from all 3 groups) were randomly selected for assessment of the reproducibility of strains and T1 values 1 month after the first measurement by another investigator (L-MW) who was blinded with regard to the data.
Statistical analysis. Quantitative data are presented as the mean AE SD or the median (interquartile range). Categorical data are presented as the number (percent). All quantitative data were checked for normality using the Kolmogorov-Smirnov test, and comparisons among the 3 groups were performed using one-way analysis of variance with Fisher's protected least significant difference multiple comparison test for between-group comparisons or the Kruskal-Wallis nonparametric test. To assess qualitative data, comparisons of the 3 groups were performed using Pearson's chisquare test or Fisher's exact test. The LGE and T1 values were only collected from the left myocardium due to the thin wall of the RV. The interobserver reproducibility of T1 mapping and ECV and strain measurements were assessed using the interclass correlation coefficient (ICC), as well as intraclass coefficient analysis. Univariate and multivariate regressions with outcomes from ECV were performed to identify the statistically significant determinants. All of the analyses were performed using IBM SPSS software, version 17.0. P values less than 0.05 (2-tailed) were considered significant.
RESULTS

Patient population.
A total of 163 subjects were recruited based on the inclusion and exclusion criteria. One patient did not finish the cardiac MRI protocol because of severe systolic heart failure. Two patients were diagnosed as having CAD after undergoing cardiac MRI. Consequently, 50 drug-naive patients newly diagnosed as having SLE, 60 patients with longstanding treated SLE, and 50 controls were included.
Assessment of interobserver variability. The interobserver variability of both LV global longitudinal strain and RV global longitudinal strain was optimal, with ICC values of 0.82 for both. Additionally, the ICC values for native myocardial T1 and native blood T1 were 0.96 and 0.99, respectively, and the ICC values for postcontrast myocardial T1 and postcontrast blood T1 were 0.98 and 0.99, respectively.
Patient characteristics. The patients enrolled in our study represented the general population of SLE patients, Table 1 , and cardiology characteristics are shown in Table 2 . The new-onset SLE and control groups had fewer numbers of women compared with the longstanding SLE group (P = 0.001), but age did not differ significantly between groups. Disease duration was much longer in the group with longstanding SLE. Immune parameters were more affected in the group with new-onset SLE, but SLE disease activity was similar between the groups (P > 0.05). In terms of cardiac clinical assessment, no current Prednisone Cardiac function and dimensions. With regard to cardiac measurements, RV mass was heavier in the group with longstanding SLE (P < 0.001 versus both the control and new-onset SLE groups) ( Table 2 ). For cardiac systolic Twelve percent of the patients with new-onset SLE had mild diastolic dysfunction (versus 10% of the patients with longstanding SLE) (P = 0.98).
Prevalence and extent of myocardial fibrosis. Regional fibrosis was detected using LGE ( Supplementary  Figure 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40671/ abstract). Interestingly, although no structural abnormalities were found in the drug-naive patients with new-onset SLE, 12% were LGE positive (Supplementary Figure 1A) , with a mean size of the scar detected by LGE of 0.5% of the LV (47 of 50 patients had a scar size within 1% of the LV), but this was not significantly different from the control group (P = 0.37) (Supplementary Figure 1B) . In the group with longstanding SLE, LGE presence and size were more prominent; 40% of the patients had LGE with a mean LGE size of 2.1% (P = 0.004 for presence of LGE and P = 0.002 for LGE size versus patients with new-onset SLE).
Diffuse tissue ECV changes were observed using T1 values and T1-induced ECV ( Table 3) . Unlike the insensitive LGE findings in the group with new-onset SLE, native myocardial T1 values were elevated in the group with newonset SLE (mean AE SD 1,369 AE 79 msec versus 1,092 AE 57 msec in the control group; P < 0.001), accompanied by elevated ECV (mean AE SD 32 AE 5% versus 24 AE 3% in the control group; P < 0.001). Sixty-four percent of the patients in the group with new-onset SLE had elevated ECV (≥2 SD above the mean in the control group). No additional increase in T1 values or ECV was detected in the group with longstanding SLE (P > 0.05 versus patients with newonset SLE). In the LGE-negative patients, a similar trend was observed; a similar extent of elevated native myocardial T1 values and ECV was detected in both SLE groups. Edema, indicated by T2-STIR, was present in similar percentages of patients in the 2 disease groups.
Since baseline parameters, such as sex, disease duration, risk factors, prior history of cardiac disease, SLE disease activity, and medications, might act as confounders, univariate and multivariate regression analyses were conducted to explore the impact of these confounders on ECV. Parameters in Tables 1-3 are explored  in Supplementary Table 2 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/ doi/10.1002/art.40671/abstract. The results showed that female sex and disease duration were the 2 indices statistically associated with ECV increases. We further conducted a stratified analysis exploring the ECV and native T1 values in women and men separately. Although men had a lower ECV (mean AE SD 26 AE 3% for men and 32 AE 5% for women in the group with new-onset SLE; 28% for men and 31 AE 5% for women with longstanding SLE) and lower native T1 value (mean AE SD 1,293 AE 41 msec for men and 1,379 AE 78 msec for women with newonset SLE; 1,342 msec for men and 1,361 AE 77 msec for women with longstanding SLE) (only 1 man was included in the group with longstanding SLE), similar statistically significant clinical increases in ECV and native T1 values compared with the controls (P < 0.001) were observed separately in women and men. Representative images of fibrotic manifestations are shown in Figure 1. LGE was absent in a representative patient with new-onset SLE, but the native myocardial T1 values were elevated, accompanied by elevated ECV. Unlike the insensitive LGE in the new-onset group, LGE could be clearly distinguished in the patients with longstanding SLE, with a similar elevation of ECV.
Change in myocardial strain. There was no difference in either the LV or RV longitudinal strain between the group with new-onset SLE and the control group (P = 0.51 and P = 0.44, respectively) (Figures 2A and  C) . However, strain was significantly reduced in the group with longstanding SLE, indicating a trend similar to that observed for LGE size. In LGE-positive patients (Figure 2B) , a peak strain decrease was observed (P = 0.08 for the group with new-onset SLE and P = 0.0001 for the group with longstanding SLE versus controls).
Correlation of myocardial indices with increase in BNP level. Table 2 and Supplementary Table 1 show that BNP level was significantly increased in the patients with Note that native T1 and postcontrast T1 were diffusively distributed in SLE patients (mainly red on the myocardium in SLE patients and yellow in the control). Bottom, Extracellular volume (ECV) values. Similar values were found for the SLE patients, and were higher than that in the control. Arrows indicate visual fibrosis.
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GUO ET AL longstanding SLE, indicating heart failure, which triggered further exploration of the myocardial indices that indicate increases in BNP level. RV and LV structural and functional indices and fibrotic and strain indices were included in univariable analyses and were included in multivariable regression analyses if significant. Pulmonary artery pressure, LV systolic function, and LV structural depression predicted increases in BNP level (coefficient 2308, SEM 4.69, T statistic 4.93, P = 0.008 for pulmonary artery pressure; coefficient 63.92, SEM 14.46, T statistic 4.42, P = 0.01 for LVEF; and coefficient À290.33, SEM 96.92, T statistic À3, P = 0.04 for LV end systolic volume/ body surface area). No fibrotic or strain indices were predictive of an increase in BNP level. Impact of SLE activity on the myocardium. Table 4 shows the impact of SLE disease activity on serum markers of cardiac injury, ventricular structure and function, and fibrotic parameters. All of the cardiac indices were found to be unrelated to SLE disease activity in both SLE groups (P > 0.05).
DISCUSSION
The main findings of this study were the following: 1) drug-naive patients with new-onset SLE, even those with inactive disease, were likely to have silent cardiac impairment; 2) SLE patients could have impairment affecting the matrix, structure, or function of the myocardium and myocardial impairment was related to SLE disease stage; 3) native myocardial T1 values and ECV, rather than currently used clinical rheumatic and cardiac disease indices, could serve as early detection markers of myocardial injury before LGE and functional decompensation; and 4) the RV is involved in cardiac impairment prior to the LV in patients without CAD.
One of the surprising findings is that the RV, rather than the LV, was affected. Thirty-three percent of the patients with longstanding SLE and 20% of those with new-onset SLE were reported to have pulmonary hypertension, which is likely to be the driver of the RV changes. These findings remained the same after we excluded patients with pulmonary hypertension. Our finding was inconsistent with the concept that patients with SLE likely have atherosclerosis and CAD (24) , contributing to LV impairment (25) . We believe that this discrepancy was due to the following. In the present study, we excluded patients with CAD, and the drug-naive patients with newonset SLE did not have steroid-related atherosclerotic disease; thus, our findings showed SLE-related myocardial impairment other than LV dysfunction from epicardial coronary disease. In other words, our study reflected more involvement of smaller and medium-sized arteries (26) , which might exhibit RV dysfunction in SLE.
Interestingly, patients with sarcoidosis, another immune-related inflammatory disorder, have similar pathologic changes in RV remodeling (27) . Sarcoidosis might also involve one or multiple organs. The most frequent and characteristic LGE site for sarcoidosis is the right side of the septum (LGE also presented mostly at the RV insertion site in SLE in our study), and the RVEF is usually reduced before the LVEF, and this reduction could occur independently of pulmonary hypertension in sarcoidosis (28) (similar to our observation in SLE). Since both diseases share common myocardial changes, we propose that RV remodeling could be a consequence of disease progression, rather than of pulmonary hypertension.
Findings for all of the cardiac indices were unrelated to SLE disease activity, prompting us to further explore specific cardiac markers. As a plausible regional fibrotic index, LGE did not sensitively reflect global fibrotic changes. However, LGE remained important in the disease appraisal. LGE was seen in patients with newonset SLE, and there was a greater incidence and extent of fibrosis in the later stages of the disease. In our study, the peak strain decrease was observed when LGE was present. From a tissue perspective, tissue fibrosis could be a pathologic cause of strain changes. Several studies have suggested that LV global longitudinal strain is more sensitive than LVEF in detecting subclinical LV systolic dysfunction (29) ; in multivariate analysis, each 1 SD decrease in LV global longitudinal strain was associated with a 75% increase in the risk of cardiovascular events (30) , and patients with the most impaired global longitudinal strain had a 3-fold risk of all-cause mortality, compared with patients with the best global longitudinal strain (31) . Thus, SLE treatment should be started before global longitudinal strain decreases and LGE.
Unlike acute parameters, such as BNP level, troponin, or T2-STIR, T1 values can reflect continuous changes in the disease. To explore the suggestion of (3) that T1 mapping may have the potential to detect subclinical myocardial involvement, we first investigated drug-naive patients with new-onset SLE in a whole-heart manner. We consistently demonstrated that native T1 values and ECV were elevated in this group; no additional elevation was detected in those with longer disease durations and medication histories (i.e., the patients with longstanding SLE). The cause of the elevation might differ from ischemic heart disease; the latter mainly represents myocardial scar and necrosis. Since SLE is possibly a small vessel disease, myocardial involvement in SLE can include myocarditis (inflammation), fibrosis replacement, or myocardial ischemia (32) , all of which can induce increases in T1 values. However, it was not possible to examine the pathologic features of myocardium in our study; it would be ideal in future studies to perform biopsies in animal models of SLE to confirm the components of abnormal myocardium. One of the advantages of T1 and ECV values is that they reflect abnormal tissue features when ventricle size, function, and strain are still within normal ranges. These advantages are independent of SLE disease activity, disease duration, or acute myocardial involvement. Additionally, T1 and ECV values have been shown to be more sensitive than electrocardiographic parameters or currently used clinical biomarkers. This finding indicates that T1 values and ECV could serve as warning signs of subclinical disease.
The impact of the present study comes mainly from 2 aspects. First, native myocardial T1 values and ECV, rather than currently used clinical rheumatic and cardiac indices, could serve as early detection markers of myocardial injury in patients with new-onset SLE. The finding that cardiac impairment occurs before the appearance of cardiovascular symptoms provides a rationale for starting cardioprotective medication at this early stage. Second, the findings of more severe myocardial remodeling with visual fibrosis appearing in patients with longstanding SLE, compared with patients with new-onset SLE, indicates the importance of antifibrotic treatment for SLE patients.
T1 values and ECV could serve as noninvasive indices for screening for subclinical disease and could alert clinicians to early clinical signs and the need for follow-up tools and targeted treatment before LGE and functional decompensation. We suggest that patients with reduced longitudinal LV peak strain (which can be simply detected by echocardiography) consider undergoing further cardiac MRI. Moreover, since native T1 and ECV yielded similar findings in this group of patients, it might also be applicable to perform noncontrast cardiac MRI (only native T1, without ECV) to assess cardiac status. This noncontrast examination not only reduces contrast-related risk, but largely reduces the scan time and is also available for patients with renal failure. The relationships between cardiac symptoms and SLE biochemical indices should be clarified in the future. In addition, SLE treatment intensity should be adjusted according to the degree of myocardial injury. Cardioprotective medication might be important once cardiac involvement is noted. Finally, future studies should focus on the effects of medication on the amelioration of myocardial tissue abnormalities, as well as structural and functional change.
Our study had some limitations. First, we did not include patients with a high likelihood of developing CAD, which might have weakened the impact of large blood vessels on myocardial injury. However, this limitation enabled us to observe inflammatory nonepicardial vascular disease on the myocardium. Second, no T1 values were analyzed on the RV because the thin right sidewall impeded objective observation. Third, it was not possible to determine the pathologic features of the myocardium in our study. Further studies should be conducted to perform biopsies in animal models of SLE to confirm the components of abnormal myocardium.
Drug-naive patients with new-onset SLE, even those with inactive disease, were likely to have silent cardiac impairment. The structural and functional changes in the myocardium were related to SLE disease stage; this association demonstrated the value of early detection of myocardial involvement. Early detection of myocardial injury before the presence of LGE and functional decompensation using native myocardial T1 values and ECV might enable the selection of optimal medical treatments. Further studies with larger sample sizes would be useful for evaluating the effect of this early detection.
